Treatment of Inflammatory Spermatic Cord Disease in Epididymo-Orchitis with M. genitalium Identified on NAAT

This protocol addresses the specific clinical scenario of inflammatory diseases of the spermatic cord, tunica vaginalis, and vas deferens occurring in the setting of epididymo-orchitis where Mycoplasma genitalium (M. genitalium) has been identified by nucleic acid amplification testing (NAAT).

When M. genitalium testing has been performed and the organism is confirmed, the treatment approach for epididymo-orchitis is specifically guided by that microbiological finding. This is a distinct management pathway from epididymo-orchitis without identified pathogen, and the antibiotic selection is directed accordingly.

Treatment goals

Improvement in scrotal pain and swelling at 3 days.

Resolution of symptoms at 2 weeks.

Negative M. genitalium test of cure at four weeks.

Management involves a targeted antibiotic course chosen specifically for activity against the confirmed organism — the complete evidence-based regimen is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/0956462417699356

Where M. genitalium testing has been performed, and the organism identified, treatment should be guided to include an appropriate antibiotic (e.g. moxifloxacin 400 mg once daily for 14 days).

The guideline includes the management of epididymitis when Mycoplasma genitalium is identified: to treat with a 14-day course of moxifloxacin, with a need for test of cure at four weeks along with a three-month look-back period for partner notification.

View source ↗